Last edition
News about "Andy Plump"
US FDA Accepts NDA under Priority Review for Takeda's Zasocitinib
The US Food and Drug Administration (FDA) has accepted Takeda’s New Drug Application (NDA) for zasocitinib under Priority Review (PR) for the treatment of moderate-to-severe plaque psoriasis, potentially redefining expectations for oral treatment.
Andy Plump | 15/09/2026 | By News Bureau
US FDA Approves Takeda's ORZEYFUL for Narcolepsy Type 1
US Food and Drug Administration (FDA) approves Takeda's ORZEYFUL (oveporexton), the first orexin therapy to treat the underlying cause of Narcolepsy Type 1 in adults.
Andy Plump | 07/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy